Invokana Lawsuit- Type 2 Diabetes Drug May Cause Ketoacidosis

Invokana Lawsuit

Zoll & Kranz, LLC Currently Investigates The Potential Invokana Lawsuit

The law firm of Zoll & Kranz, LLC is continuing to investigate the potential link between these drugs and ketoacidosis. In March 2013, the FDA approved Invokana (canagliflozin) tablets for adults with Type 2 Diabetes to improve glycemic control.

A New Class of Drugs

When Invokana was approved, it was the first in a class known as “sodium-glucose co-transporter 2 (SGLT2).” Invokana works by blocking the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in diabetics who have elevated blood glucose levelsInvokana Lawsuit

The Dangers of Invokana

In March 2015, two years after approval, the FDA released a safety announcement that the Invokana and other SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. This condition is known as ketoacidosis and could require hospitalization. Symptoms of ketoacidosis are:

  • Difficulty breathing
  • Nausea
  • Vomiting
  • Abdominal pain
  • Confusion
  • Unusual fatigue or sleepiness
  • A search of the FDA Adverse Event Reporting System (FAERS) database identified 20 cases of acidosis reported as diabetic ketoacidosis (DKA), ketoacidosis, or ketosis in patients treated with SGLT2 inhibitors from March 2013 to June 6, 2014 . All patients required emergency room visits or hospitalization to treat the ketoacidosis. Since June 2014, the FDA has continued to receive additional FAERS reports for DKA and ketoacidosis in patients treated with SGLT2 inhibitors.

    SGLT2 Inhibitors Brands:

  • Invokana (canagliflozin)
  • Invokamet (canagliflozin and metformin)
  • Farxiga (dapagliflozin)
  • Xigduo XR (dapagliflozin and metformin extended-release)
  • Jardiance (empagliflozin)
  • Glyxambi (empagliflozin and linagliptin)
  • Recent News: Invokana and Invokamet May Cause Bone Fractures
    The FDA recently added a new Warning and Precaution to the Invokana and Invokamet drug labels regarding the increases risk of bone fractures and decreased bone mineral density. The other SGLT2 inhibitors are still being evaluated by the FDA to see if their label needs to be updated.

    The drug safety communication in September 2015 explained that fractures can occur as early as 12 weeks after starting the medication. Furthermore, they found a link to decreased bone mineral density in the hip and lower spine. The FDA says,”Do not stop or change your diabetes medicines without first talking to you health care professional.”

    Contact Our Invokana Mass Tort Lawyers

    Please contact our product liability attorneys if you have any questions on this investigation or if you think you have been injured by your SGLT2 medication. You may be able to file a lawsuit. The lawyers can be reached toll-free at 888-841-9623 or our online live chat representative is always available.

    Please fill out the form for a complimentary case evaluation for Invokana.

    Free Case
    Evaluation

    Did you take Invokana?

    Have you been diagnosed with Type 2 diabetes?

    When did you start taking Invokana?

    Were you diagnosed with ketoacidosis or diabetic ketoacidosis (DKA)?

    Were you hospitalized for ketoacidosis?

    Yes, I have read and understand the privacy policy.

    Please leave this field empty.